24 / 27
1. Vogel A
et al
. Abstract presented at the 2017 ESMO Annual Congress, Madrid, Spain. Sep 8–12, 2017
.
Conclusions: HRQoL Analysis
§
>98% of patients completed the questionnaires at each time point.
§
HRQoL declined in both arms
during the treatment.
§
For most domains, the impact on HRQoL was generally similar between lenvatinib and
sorafenib.
§
Patients on
lenvatinib
experienced
clinically meaningful delays in deterioration in role
function, general cancer pain, diarrhoea, nutrition, and body image
vs sorafenib:
Ø
There were no nominally significant improvements in any of the HRQoL
domains with sorafenib compared to lenvatinib.
HRQoL = health-related quality of life.